Abstract | OBJECTIVE: To review the pharmacology, antimicrobial activity, pharmacokinetics, clinical applications, and safety of ramoplanin, a lipoglycodepsipeptide antibiotic. DATA SOURCES: Information was obtained from MEDLINE and BIOSIS databases (1984-August 2004) and Oscient Pharmaceuticals using the key words ramoplanin, A 16686, A 16686A, and MDL 62198. STUDY SELECTION AND DATA EXTRACTION: Available English-based articles and abstracts were reviewed, along with information from Oscient Pharmaceuticals. DATA SYNTHESIS:
Ramoplanin exerts its bactericidal activity against gram-positive aerobic and anaerobic bacteria by blocking peptidoglycan synthesis via lipid II. In vitro susceptibility reports have demonstrated efficacy against antibiotic-resistant gram-positive pathogens. Cross-resistance has not been documented with vancomyin and other glycopeptides. Clinical trials are investigating ramoplanin's oral administration for treatment of Clostridium difficile-associated diarrhea. Previous clinical trials had evaluated the suppression of colonization of vancomycin-resistant Enterococcus with ramoplanin. Adverse effects are minimal, and drug-drug interactions have not been documented. CONCLUSIONS: The completion of clinical trials will determine whether ramoplanin has a promising role as a treatment option for diarrhea due to C. difficile.
|
Authors | Debra K Farver, Dennis D Hedge, Steven C Lee |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 39
Issue 5
Pg. 863-8
(May 2005)
ISSN: 1060-0280 [Print] United States |
PMID | 15784805
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anti-Bacterial Agents
- Depsipeptides
- ramoplanin
|
Topics |
- Adult
- Anti-Bacterial Agents
(adverse effects, pharmacokinetics, therapeutic use)
- Clinical Trials as Topic
- Clostridioides difficile
(drug effects, pathogenicity)
- Depsipeptides
(adverse effects, pharmacokinetics, therapeutic use)
- Diarrhea
(drug therapy)
- Humans
- Microbial Sensitivity Tests
|